Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

NCT03313778 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT03313778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03313778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
Lead sponsor
ModernaTX, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 14, 2017
Completion date
November 21, 2027
Enrollment
161 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors